Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 14.9% year on year to $30...
Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 14.9% year on year to $3...
Healthcare tech company Omnicell (NASDAQ:OMCL) will be announcing earnings results this Tuesday before market hours. Here’s what to look for. Omnicell met an...
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Omnicell (NASDAQ:OMCL) and it...
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Over the past six months, Omnicell has been a great trade, beating the S&P 500 by 19.8%. Its stock price has climbed to $41.48, representing a healthy 26.4% ...
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to 150 days. The rapid reimposition of trade barriers creates significant uncertainty for companies across multiple sectors that depend on international supply chains and global trade. Investors are now weighing the potential impact of these new duties on corporate earnings and broader economic activity.
Omnicell’s fourth quarter was met with a significant negative market reaction, as the company delivered revenue in line with Wall Street expectations but posted a notable shortfall in non-GAAP profitability. Management attributed the quarter’s performance to robust demand for its point-of-care connected devices, particularly the XT S10, and highlighted strong annual recurring revenue momentum. However, mix shifts in product and customer base, as well as higher operating costs tied to new product introductions and customer experience initiatives, weighed on margins. CFO Baird Radford acknowledged that “non-GAAP EBITDA was at the lower end of our guidance,” citing deliberate investments in sales force expansion and innovation.
Healthcare tech company Omnicell (NASDAQ:OMCL) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 2.3% year on year to $314 million. The company expects next quarter’s revenue to be around $305 million, coming in 8.2% above analysts’ estimates. Its non-GAAP profit of $0.40 per share was 19.4% below analysts’ consensus estimates.
Shares of healthcare tech company Omnicell (NASDAQ:OMCL)
fell 18.4% in the morning session after the company reported fourth-quarter earnings that fell short of Wall Street expectations and provided a disappointing forecast for the 2026 financial year.
Healthcare tech company Omnicell (NASDAQ:OMCL) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 2.3% year on year to $314 million. The company expects next quarter’s revenue to be around $305 million, coming in 8.2% above analysts’ estimates. Its non-GAAP profit of $0.40 per share was 19.4% below analysts’ consensus estimates.
Healthcare tech company Omnicell (NASDAQ:OMCL)
will be announcing earnings results this Thursday before market hours. Here’s what investors should know.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare technology for providers industry, including Omnicell (NASDAQ:OMCL) and its peers.
